Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02550249 : Neoadjuvant Nivolumab in Glioblastoma
PhasePhase 2
AgesMin: 1 Year Max: N/A
Eligibility
Inclusion Criteria:

- Written informed consent.

- Patients must be willing and able to comply with scheduled visits, treatment
schedule, laboratory testing and other requirements of the study.

- Patients with GBM that are candidates to primary or salvage resection surgery,
according to the following criteria:

- Patients may have received previous treatments for GBM. There is no limit on previous
treatment lines, as long as the other inclusion criteria are met.

- Patients in whom surgery can be safely delayed for a minimum period of 2 weeks
following the administration of the first dose of nivolumab, in the opinion of the
investigator.

- Eastern Cancer Oncology Group (ECOG) performance status of 0-1. Patients with ECOG>1
due to neurological symptoms considered to be reversible following surgery, according
to investigator´s criteria will be eligible

- Life expectancy >12 weeks.

- Adequate organ function defined by:

1. Bone Marrow Reserve: white blood cells (WBC): ?2000/ mm3 absolute neutrophil
count (ANC) ?1500x 109/L; platelet count ?100000/ mm3 100 x 109/L; hemoglobin
?9.0 g/dL).

2. Hepatic: bilirubin <1.5 times the upper limit of normality (ULN), AST and ALT
<3.0 × ULN (BR< 3 x ULN for patients with Gilbert´s Syndrome).

3. Renal: creatinine < 1.5 x ULN or estimated creatinine clearance > 40 ml/min,
using the Cockcroft-Gault formula.

Exclusion Criteria:

- Presence of extracranial disease.

- Any serious or uncontrolled medical disorder that, in the opinion of the
investigator, may increase the risk associated with study participation or study drug
administration, impair the ability of the subject to receive the planned therapy
(including brain surgery), or interfere with the interpretation of study results.

- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,
type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only
requiring hormone replacement, psoriasis not requiring systemic treatment, or
conditions not expected to recur in the absence of an external trigger are permitted
to enroll.

- Previous treatment with a PD-1, PDL1 or CTLA-4 targeted therapy

- Treatment with any anti-cancer drug or radiation therapy within the last 14 days. A
shorter interval can be approved by the principal investigator, if deemed
appropriate.

- Patients should be excluded if they have a condition requiring systemic treatment
with either corticosteroids (>10 mg daily prednisone equivalents), with the exception
of control of cerebral edema, or other immunosuppressive medications within 14 days
of study drug administration. Inhaled or topical steroids and adrenal replacement
doses > 10 mg daily prednisone equivalents are permitted in the absence of active
autoimmune disease.

- Pregnant or breastfeeding patients.

- Known history of testing positive for human immunodeficiency virus (HIV) or known
acquired immunodeficiency syndrome (AIDS). Routine testing is not required.

- Positive tests for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus
ribonucleic acid (HCV RNA) indicating active or chronic infection.

- History of allergy to study drug components or of severe hypersensitivity reactions
to any monoclonal antibodies.

- Prisoners or subjects who are involuntarily incarcerated or who are compulsorily
detained for treatment of either a psychiatric or physical (eg, infectious disease)
illness.

- Subjects unable (due to existent medical condition, e.g, pacemaker or implantable
cardioverter defibrillator device) or unwilling to have a head contrast enhanced MRI
and/or a CT scan of the brain.

- Concomitant or prior malignancy that, in the opinion of the investigator
contraindicates GBM surgery or can interfere with the results of the study, in the
opinion of the investigator.

- Known drug or alcohol abuse.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02550249      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740